Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coletta, D. K
Right arrow Articles by Bailey, C. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coletta, D. K
Right arrow Articles by Bailey, C. J
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data

Dawn K Coletta

Division of Diabetes, Department of Medicine, The University of Texas Health Science Center at San Antonio, Texas 78229-3900, US

Sarah H Bates

Faculty of Life Sciences, University College London, London, UK

Robert B Jones

RenaSci Consultancy Limited, BioCity, Nottingham, UK

Clifford J Bailey

School of Life and Health Sciences, Aston University, Birmingham, UK

The satiety agent sibutramine acts in part through a primary amine metabolite, M2. To investigate whether M2 could affect glycaemia independently of satiety and weight loss, groups of normal mice received a single dose of M2 (1 or 10 mg/kg) and food was withheld. Compared with controls (who received vehicle only), M2 (10 mg/kg) decreased basal plasma glucose concentrations, with a maximal decrease of about 25% at 4-8 hours (p<0.05). Soleus muscles were isolated from the mice at intervals: insulin-mediated glucose uptake by the muscles from controls progressively decreased over 24 hours whereas uptake was maintained by muscles from M2-treat-ed mice. Hepatic gluconeogenesis was reduced about 40% by liver snips isolated from M2-treated mice after 24 hours (p<0.05).

These preliminary results suggest that the M2 metabolite of sibutramine can reduce glycaemia, maintain insulin-mediated muscle glucose uptake and reduce hepatic gluconeogenesis independently of satiety and weight loss.

Key Words: sibutramine • basal plasma glucose • insulin-mediated glucose uptake • hepatic gluconeogenesis • mice

Diabetes and Vascular Disease Research, Vol. 3, No. 3, 186-188 (2006)
DOI: 10.3132/dvdr.2006.028
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
Y.-Y. Lin, C.-W. Hsu, S.-J. Chu, and S.-H. Tsai
Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam
QJM, March 1, 2008; 101(3): 243 - 245.
[Full Text] [PDF]